Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PANK3 | Q9H999 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | ME2 | P23368 | 2/20 | 0.37 |
| ▸ | ME1 | P48163 | 2/20 | 0.37 |
| ▸ | ME3 | Q16798 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3334403 | 0.87 | ALDH1A1 (0.45) | MAPTHTTMEN1KMT2A | |
| SCHEMBL3338988 | 0.87 | KDM4E (0.52) | PANK3MAPTKDM4EHTTMEN1 | |
| SCHEMBL3338768 | 0.84 | MEN1 (0.50) | PANK3MAPTKDM4ENOD2MEN1 | |
| SCHEMBL8170094 | 0.79 | KDM4E (0.40) | MAPTKDM4EHTTPDGFRBME2 | |
| SCHEMBL3333658 | 0.77 | ME2 (0.48) | PANK3MAPTKDM4EME2ME1 | |
| SCHEMBL3334388 | 0.76 | KDM4E (0.40) | PANK3KDM4EMEN1KMT2A | |
| SCHEMBL3334926 | 0.75 | KDM4E (0.49) | PANK3KDM4EMEN1KMT2A | |
| SCHEMBL3332826 | 0.74 | GRM1 (0.52) | KDM4E | |
| SCHEMBL3333201 | 0.74 | GRM1 (0.52) | KDM4E | |
| SCHEMBL3332832 | 0.74 | GRM1 (0.52) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | claimed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | GRM5, GRM1, GRM2 | PANK3 3656/4885MAPT 2485/4885KDM4E 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.